Integra LifeSciences Holdings Corporation · NASDAQ:IART

Integra LifeSciences — Q1 2022 Earnings Presentation

19 slides from Integra LifeSciences's earnings presentation, Apr 27, 2022

  1. Slide 1: Q1 2022 Earnings Presentation

    Q1 2022 EARNINGS PRESENTATION APRIL 27, 2022

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted fre

  4. Slide 4: Executing On Our Strategy

    Executing On Our Strategy Q1 Financial Performance Business Highlights Total revenue $376.6 million – above high end of guidance Broad surgical procedure recovery across portfolio • Procedure volumes steadily improved in March • ≥ 5% organic growth in CSS and TT • Supply met accelerated demand Focus

  5. Slide 5: First Quarter Financial Highlights

    First Quarter Financial Highlights • 4.6% reported growth Revenue $376.6 • $12M above high end of guidance range Organic • 5.0% Global CSS organic growth • 6.0% U.S. organic growth Revenue 5.6% Growth1 • 6.9% Global TT organic growth • 4.8% Intl. organic growth Adj EBITDA 24.8% Adj. gross margins in

  6. Slide 6: Codman Specialty Surgical Q1 Revenue

    Codman Specialty Surgical Q1 Revenue Revenues Q1’22 Q1’21 Growth Reported $247.3M $241.2M 2.5% Q1 2022 Organic1 $248.4M $236.6M 5.0% Revenue Composition Q1 2022 Growth and Performance Drivers2 Instruments Neurosurgery Instruments International 21.3% 5.8% 2.1% Mid-Single Digits • Neurosurgery – High

  7. Slide 7: Tissue Technologies Q1 Revenue

    Tissue Technologies Q1 Revenue Revenues Q1’22 Q1’21 Growth Reported $129.3M $118.8M 8.8% Q1 2022 Organic1 $127.1M $118.8M 6.9% Revenue Composition Q1 2022 Growth and Performance Drivers2 Private Wound Reconstruction Private Label International Label 26.8% 4.1% 15.2% Mid-Single Digits • Wound Reconst

  8. Slide 8: Q1 2022 Financial Results ($M except per share data)

    Q1 2022 Financial Results ($M except per share data) Total Revenue Adj. Gross Profit Adj. EBITDA Adj. EPS Reported 4.6% 40bps Margin (20bps) Margin +7.2% Organic 5.6% $360.1 $376.6 $93.5 $254.8 $89.9 $242.4 $40 0.0 1 $30 0.0 20 100 1.2 $0.8 0 1.2 $35 0.0 $25 0.0 15 90 1 $0.7 5 $0.74 1 $0.69 80 $30 0

  9. Slide 9: Balance Sheet and Cash Flow Performance

    Balance Sheet and Cash Flow Performance Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%) Summary Balance Sheet ($M) 12/31/21 3/31/22 FCF Capex 350 Cash and Cash Equivalents $513 $407 $287.7 300 $252.1 $50.7 Total Debt $1,563 $1,562 $29.0 250 Net Debt $1,050 $1,155 90 $69.1 200 80 $

  10. Slide 10: Q2 2022 and FY 2022 Outlook

    Q2 2022 and FY 2022 Outlook Q2 Reported Revenue Guidance Bridge ($M) Q2 2022 2.8% - 4.8% $390 $392 - $400 • Revenue: $392M-$400M ~($2) ~($7) • Reported Growth +0.5% to +2.5% • Organic Growth +2.8% to +4.8% • Adj. EPS $0.78 - $0.82 2022 Reported Revenue Guidance Bridge ($M) FY 2022 3.8% - 5.2% • Reaf

  11. Slide 11: Integra Growth Catalysts

    Integra Growth Catalysts Near- to Mid-Term Growth Catalysts First Quarter Performance & Progress Diverse and Inclusive Teams • Post-COVID procedure growth recovery  Broad-based organic growth despite Focused on COVID-related disruptions in beginning Getting Things Rigorous • International opportuni

  12. Slide 12: Appendix: Non-GAAP Reconciliations

    Appendix Non-GAAP Reconciliations

  13. Slide 13: First Quarter 2022 Financial Results

    First Quarter 2022 Financial Results % of Revenues Q1 2022 Q1 2021 Change Total Revenues $376.6 $360.1 4.6% Gross Margin 62.1% 59.5% +260BPS Adj. Gross Margin(1) 67.7% 67.3% +40BPS Net Income $32.9 $45.4 (27.5%) Adj. Net Income(1) $62.0 $59.0 5.1% Adj. EBITDA Margin(1) 24.8% 25.0% -20BPS Diluted Sha

  14. Slide 14: First Quarter 2022 Organic Growth Reconciliation

    First Quarter 2022 Organic Growth Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Neurosurgery $194.7 $189.3 Instruments $52.6 $52.0 Total Codman Specialty Surgical $247.3 $241.2 Wound Reconstruction and Care $94.6 $88.7 Private Label $34.7 $30.1 Total Tissue T

  15. Slide 15: First Quarter 2022 Adjusted EBITDA Margin Reconciliation

    First Quarter 2022 Adjusted EBITDA Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 GAAP Net Income $32.9 $45.4 Depreciation 9.6 9.4 Intangible asset amortization 20.1 22.5 Other (income), net (2.1) (3.3) Interest expense, net 10.3 11.2 Income tax expense

  16. Slide 16: First Quarter 2022 Adjusted EPS Reconciliation

    First Quarter 2022 Adjusted EPS Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 GAAP Net Income $32.9 $45.4 Acquisition, divestiture and integration-related charges (1) 0.6 (27.0) Structural optimization charges 6.3 3.9 EU Medical Device Regulation 9.5 5.7 Inta

  17. Slide 17: First Quarter 2022 and 2021 (TTM) Adjusted Free Cash Flow Reconciliation

    First Quarter 2022 and 2021 (TTM) Adjusted Free Cash Flow Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 TTM 2022 TTM 2021 Net Cash from Operating Activities $44.3 $69.1 $287.7 $252.1 Purchases of Property and Equipment ($9.3) ($6.7) ($50.7) ($29.0) Free Cash

  18. Slide 18: First Quarter 2022 Gross Margin Reconciliation

    First Quarter 2022 Gross Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Reported Gross Profit $234.1 $214.2 Structural optimization charges 2.9 1.8 Acquisition, divestiture and integration-related charges 0.9 8.0 EU Medical Device Regulation 0.7 0.3 Int

  19. Slide 19: First Quarter 2022 Adjusted SG&A Reconciliation

    First Quarter 2022 Adjusted SG&A Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Reported SG&A $159.9 $156.6 Structural optimization charges 3.3 1.6 Acquisition, divestiture and integration-related charges 2.1 7.8 EU Medical Device Regulation 3.5 2.1 Adjusted S

Integra LifeSciences Holdings — Q1 2022 Earnings Presentation on 6ix